Wednesday, January 28, 2026
FDA Allows Repeat Administration of iDose TR
Updated labeling permits re-administration of the intracameral travoprost implant under a defined treatment protocol.
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-gp-staging.hbrsd.com/media/4tbpmbe0/010926-omd-web-covers-staff.jpg
Ophthalmology Management
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-gp-staging.hbrsd.com/media/yegf1tcf/cover_jan26_web_new.jpg
Retinal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-gp-staging.hbrsd.com/media/th3js22v/0126-gp-cover-web.jpg
Glaucoma Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-gp-staging.hbrsd.com/media/0jsmmz3o/op_1025_cover_final.jpg
Ophthalmic Professional
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-gp-staging.hbrsd.com/media/jdnlmuh3/1025-oasc-cover-final.jpg
The Ophthalmic ASC
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-gp-staging.hbrsd.com/media/aqbjxwjw/pp-cover.jpg
Presbyopia Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-gp-staging.hbrsd.com/media/npjdtl1w/cp_november_cover.jpg
Corneal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-gp-staging.hbrsd.com/media/mvqdq2hc/nrp_cover_october_2024.jpg
New Retinal Physician
Wednesday, January 28, 2026
Updated labeling permits re-administration of the intracameral travoprost implant under a defined treatment protocol.
Monday, January 26, 2026
The first patient has been enrolled in the ADAPT trial, which will assess the safety and effectiveness of a titratable shunt for IOP control.
Friday, January 23, 2026
A pair of registrational trials will compare the company’s bimatoprost-eluting lens to a standard lens plus drops.
Tuesday, January 13, 2026
The platform is designed to support continuous glaucoma surveillance using home-based testing and remote care management.